Company Overview and News

 
Murray Goulburn CEO to step down after Saputo takeover

2018-04-19 reuters
(Reuters) - Dairy processor Murray Goulburn Co-operative Ltd (MGC.AX) on Thursday said its CEO Ari Mervis would step down upon the completion of the company’s $1 billion takeover by Canada’s Saputo Inc (SAP.TO).
Upvote Downvote

 
Aussie food company’s $1.3b sale

2018-04-05 ntnews.com.au
Dairy farmer James Munro's impassioned plea to Murray Goulburn at a Cobden shareholder's meeting has gone viral. Video: Jonathan Munro
Upvote Downvote

 
Higher milk prices tipped to eat into Fonterra's profit

2017-09-21 nzherald.co.nz
Fonterra is expected to produce a slightly weaker annual result on Monday as higher farmgate milk prices, which act as a higher input cost, eat into its margins.
Upvote Downvote

 
Wesfarmers slide keeps ASX in red

2017-06-07 theage.com.au
Shares were buoyed by slightly better-than-expected economic growth numbers, but a slide in Wesfarmers kept the market in the red, while sentiment remained fragile ahead of a number of global risk events this week.
Upvote Downvote

 
Wesfarmers slide keeps ASX in red

2017-06-07 smh.com.au
Shares were buoyed by slightly better-than-expected economic growth numbers, but a slide in Wesfarmers kept the market in the red, while sentiment remained fragile ahead of a number of global risk events this week.
Upvote Downvote

 
ASX eases as ANZ result spooks bank investors

2017-05-02 theage.com.au
A disappointing ANZ earnings result was enough to trigger a sell-off in the big banks on Tuesday, but gains elsewhere on the ASX helped limit the losses.
Upvote Downvote

 
ASX eases as ANZ result spooks bank investors

2017-05-02 smh.com.au
A disappointing ANZ earnings result was enough to trigger a sell-off in the big banks on Tuesday, but gains elsewhere on the ASX helped limit the losses.
Upvote Downvote

 
Fortescue rally drives ASX higher

2016-10-25 theage.com.au
A strengthening iron ore price, a slew of earnings updates and a buoyant Fortescue Metals saw investors pile into iron ore miners on Tuesday. 
Upvote Downvote

 
Fortescue rally drives ASX higher

2016-10-25 smh.com.au
A strengthening iron ore price, a slew of earnings updates and a buoyant Fortescue Metals saw investors pile into iron ore miners on Tuesday. 
Upvote Downvote

 
Oil fuels ASX gains whle investors shrug off US debate

2016-10-20 theage.com.au
Shares edged higher on Thursday, driven by a steady stream of equity news amid the noise surrounding the third and final US presidential debate.
Upvote Downvote

 
Oil fuels ASX gains whle investors shrug off US debate

2016-10-20 smh.com.au
Shares edged higher on Thursday, driven by a steady stream of equity news amid the noise surrounding the third and final US presidential debate.
Upvote Downvote

 
Woolies in milk shake-up

2016-07-29 perthnow.com.au
TROUBLED dairy co-operative Murray Goulburn has lost its contract to supply supermarket giant Woolworths with private-label cheese, UHT, adult milk powder and cream.
Upvote Downvote

 
Woolies ditches private label dairy supplier

2016-07-29 perthnow.com.au
WOOLWORTHS has dumped the supplier of its private label dairy products, in a further blow to troubled producer Murray Goulburn.
Upvote Downvote

 
Cheesed off: Murray Goulburn takes $100m-a-year hit on Woolworths contract loss

2016-07-29 theage.com.au
Australia's largest milk processor, Murray Goulburn Co-operative, has taken another hit, with Woolworths dumping it as its supplier of many of its private-label dairy products.
Upvote Downvote

 
Cheesed off: Murray Goulburn takes $100m-a-year hit on Woolworths contract loss

2016-07-29 smh.com.au
Australia's largest milk processor, Murray Goulburn Co-operative, has taken another hit, with Woolworths dumping it as its supplier of many of its private-label dairy products.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

12h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...